Oculis Reports Q1 2024 Financial Results and Provides Company Updates


ZUG, Switzerland, May 08, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced results for the three-month period ended March 31, 2024, and an overview of the Company’s progress.

Read this article:
Oculis Reports Q1 2024 Financial Results and Provides Company Updates

Related Posts